Celcuity Inc. (CELC) Income Statement

The $94K in revenue for 2026Q2, though immaterial, represents the first meaningful commercial activity following the FDA approval of REVTORPYK. This suggests the company is beginning to monetize its therapeutic asset, but the scale is negligible relative to the R&D and SG&A investments. Investors should monitor the trajectory of this revenue line as it will determine whether the company can transition from a capital-consuming entity to a self-sustaining one. The absence of revenue in prior quarters highlights the binary nature of the business model, where success hinges on the commercial execution of gedatolisib.

The sharp increase in SG&A from $3.0M in 2024Q4 to $35.0M in 2026Q2 indicates a strategic pivot toward building a commercial organization, likely in anticipation of the gedatolisib launch. R&D remains the largest cost line, consistent with late-stage clinical development, but the recent spike in SG&A suggests the company is prioritizing market access and sales force readiness. This cost structure implies that operating losses will continue to widen until revenue scales, and investors should assess whether the company can achieve sufficient market penetration to offset these fixed costs. The elevated burn rate, with quarterly operating losses exceeding $66M, underscores the urgency of commercial success.

The lack of revenue means that operating leverage is currently non-existent; every dollar of R&D and SG&A directly increases the operating loss. The sequential increase in operating expenses, particularly the jump in SG&A, suggests that the company is investing ahead of the commercial launch, but this creates a period of negative operating leverage. If revenue ramps as expected, the high fixed cost base could provide significant operating leverage on the upside, but until then, losses will continue to mount. The company's ability to manage this transition will be critical, as any delay in revenue generation would exacerbate the cash burn.

The approval of gedatolisib is the single most important event in the company's history, as it de-risks the core asset and provides a path to revenue. The subsequent positive results in the PIK3CA MT cohort further expand the potential market, suggesting a broader label opportunity. However, the commercial launch is still in its early stages, and the company must now execute on reimbursement, market access, and physician adoption. The lasting impact of this inflection will depend on the company's ability to convert regulatory approval into sustainable revenue growth, which remains unproven.